RT Journal Article
SR Electronic
T1 FinnGen: Unique genetic insights from combining isolated population and national health register data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.03.22271360
DO 10.1101/2022.03.03.22271360
A1 Kurki, Mitja I.
A1 Karjalainen, Juha
A1 Palta, Priit
A1 Sipilä, Timo P.
A1 Kristiansson, Kati
A1 Donner, Kati
A1 Reeve, Mary P.
A1 Laivuori, Hannele
A1 Aavikko, Mervi
A1 Kaunisto, Mari A.
A1 Loukola, Anu
A1 Lahtela, Elisa
A1 Mattsson, Hannele
A1 Laiho, Päivi
A1 Della Briotta Parolo, Pietro
A1 Lehisto, Arto
A1 Kanai, Masahiro
A1 Mars, Nina
A1 Rämö, Joel
A1 Kiiskinen, Tuomo
A1 Heyne, Henrike O.
A1 Veerapen, Kumar
A1 Rüeger, Sina
A1 Lemmelä, Susanna
A1 Zhou, Wei
A1 Ruotsalainen, Sanni
A1 Pärn, Kalle
A1 Hiekkalinna, Tero
A1 Koskelainen, Sami
A1 Paajanen, Teemu
A1 Llorens, Vincent
A1 Gracia-Tabuenca, Javier
A1 Siirtola, Harri
A1 Reis, Kadri
A1 Elnahas, Abdelrahman G.
A1 Aalto-Setälä, Katriina
A1 Alasoo, Kaur
A1 Arvas, Mikko
A1 Auro, Kirsi
A1 Biswas, Shameek
A1 Bizaki-Vallaskangas, Argyro
A1 Carpen, Olli
A1 Chen, Chia-Yen
A1 Dada, Oluwaseun A.
A1 Ding, Zhihao
A1 Ehm, Margaret G.
A1 Eklund, Kari
A1 Färkkilä, Martti
A1 Finucane, Hilary
A1 Ganna, Andrea
A1 Ghazal, Awaisa
A1 Graham, Robert R.
A1 Green, Eric
A1 Hakanen, Antti
A1 Hautalahti, Marco
A1 Hedman, Åsa
A1 Hiltunen, Mikko
A1 Hinttala, Reetta
A1 Hovatta, Iiris
A1 Hu, Xinli
A1 Huertas-Vazquez, Adriana
A1 Huilaja, Laura
A1 Hunkapiller, Julie
A1 Jacob, Howard
A1 Jensen, Jan-Nygaard
A1 Joensuu, Heikki
A1 John, Sally
A1 Julkunen, Valtteri
A1 Jung, Marc
A1 Junttila, Juhani
A1 Kaarniranta, Kai
A1 Kähönen, Mika
A1 Kajanne, Risto M.
A1 Kallio, Lila
A1 Kälviäinen, Reetta
A1 Kaprio, Jaakko
A1 Kerimov, Nurlan
A1 Kettunen, Johannes
A1 Kilpeläinen, Elina
A1 Kilpi, Terhi
A1 Klinger, Katherine
A1 Kosma, Veli-Matti
A1 Kuopio, Teijo
A1 Kurra, Venla
A1 Laisk, Triin
A1 Laukkanen, Jari
A1 Lawless, Nathan
A1 Liu, Aoxing
A1 Longerich, Simonne
A1 Mägi, Reedik
A1 Mäkelä, Johanna
A1 Mäkitie, Antti
A1 Malarstig, Anders
A1 Mannermaa, Arto
A1 Maranville, Joseph
A1 Matakidou, Athena
A1 Meretoja, Tuomo
A1 Mozaffari, Sahar V.
A1 Niemi, Mari EK.
A1 Niemi, Marianna
A1 Niiranen, Teemu
A1 O’Donnell, Christopher J.
A1 Obeidat, Ma’en
A1 Okafo, George
A1 Ollila, Hanna M.
A1 Palomäki, Antti
A1 Palotie, Tuula
A1 Partanen, Jukka
A1 Paul, Dirk S.
A1 Pelkonen, Margit
A1 Pendergrass, Rion K.
A1 Petrovski, Slavé
A1 Pitkäranta, Anne
A1 Platt, Adam
A1 Pulford, David
A1 Punkka, Eero
A1 Pussinen, Pirkko
A1 Raghavan, Neha
A1 Rahimov, Fedik
A1 Rajpal, Deepak
A1 Renaud, Nicole A.
A1 Riley-Gillis, Bridget
A1 Rodosthenous, Rodosthenis
A1 Saarentaus, Elmo
A1 Salminen, Aino
A1 Salminen, Eveliina
A1 Salomaa, Veikko
A1 Schleutker, Johanna
A1 Serpi, Raisa
A1 Shen, Huei-yi
A1 Siegel, Richard
A1 Silander, Kaisa
A1 Siltanen, Sanna
A1 Soini, Sirpa
A1 Soininen, Hilkka
A1 Sul, Jae H.
A1 Tachmazidou, Ioanna
A1 Tasanen, Kaisa
A1 Tienari, Pentti
A1 Toppila-Salmi, Sanna
A1 Tukiainen, Taru
A1 Tuomi, Tiinamaija
A1 Turunen, Joni A.
A1 Ulirsch, Jacob C.
A1 Vaura, Felix
A1 Virolainen, Petri
A1 Waring, Jeffrey
A1 Waterworth, Dawn
A1 Yang, Robert
A1 Nelis, Mari
A1 Reigo, Anu
A1 Metspalu, Andres
A1 Milani, Lili
A1 Esko, Tõnu
A1 Fox, Caroline
A1 Havulinna, Aki S.
A1 Perola, Markus
A1 Ripatti, Samuli
A1 Jalanko, Anu
A1 Laitinen, Tarja
A1 Mäkelä, Tomi
A1 Plenge, Robert
A1 McCarthy, Mark
A1 Runz, Heiko
A1 Daly, Mark J.
A1 Palotie, Aarno
YR 2022
UL http://medrxiv.org/content/early/2022/03/06/2022.03.03.22271360.abstract
AB Population isolates such as Finland provide benefits in genetic studies because the allelic spectrum of damaging alleles in any gene is often concentrated on a small number of low-frequency variants (0.1% ≤ minor allele frequency < 5%), which survived the founding bottleneck, as opposed to being distributed over a much larger number of ultra--rare variants. While this advantage is well-- established in Mendelian genetics, its value in common disease genetics has been less explored. FinnGen aims to study the genome and national health register data of 500,000 Finns, already reaching 224,737 genotyped and phenotyped participants. Given the relatively high median age of participants (63 years) and dominance of hospital-based recruitment, FinnGen is enriched for many disease endpoints often underrepresented in population-based studies (e.g., rarer immune-mediated diseases and late onset degenerative and ophthalmologic endpoints). We report here a genome-wide association study (GWAS) of 1,932 clinical endpoints defined from nationwide health registries. We identify genome--wide significant associations at 2,491 independent loci. Among these, finemapping implicates 148 putatively causal coding variants associated with 202 endpoints, 104 with low allele frequency (AF<10%) of which 62 were over two-fold enriched in Finland.We studied a benchmark set of 15 diseases that had previously been investigated in large genome-wide association studies. FinnGen discovery analyses were meta-analysed in Estonian and UK biobanks. We identify 30 novel associations, primarily low-frequency variants strongly enriched, in or specific to, the Finnish population and Uralic language family neighbors in Estonia and Russia.These findings demonstrate the power of bottlenecked populations to find unique entry points into the biology of common diseases through low-frequency, high impact variants. Such high impact variants have a potential to contribute to medical translation including drug discovery.Competing Interest StatementMervi Aavikko: Lecturing fee and congress trip reimbursement from Ipsen and Novartis (unrelated to this work); Abdelrahman G. Elnahas: Employee of University of Tartu; Kirsi Auro: Employee of GlaxoSmithKline; Shameek Biswas: Employee of Bristol Myers Squibb; Chia-Yen Chen: Employee of Biogen; Zhihao Ding: Employee of Boehringer Ingelheim; Margaret G. Ehm: Employee of GlaxoSmithKline; Kari Eklund: Consultation fees from Sobi, and Orion corporation; Robert R. Graham: Employee of Maze Therapeutics; Eric M. Green: Employee of Maze Therapeutics; Asa K. Hedman: Employee of Pfizer Inc.; Xinli Hu: Employee of Pfizer Inc.; Adriana Huertas-Vazquez: Employee of Merck; Julie Hunkapiller: Employee of Genentech; Howard Jacob: Employee of AbbVie Inc.; Jan-Nygaard Jensen: Employee of Boehringer Ingelheim; Heikki Joensuu: Senior consultant; Orion Pharma Orion Corporation; Chairman of the Scientific Advisory Board, Neutron Therapeutics; Deciphera Pharmaceuticals, a fee for acting as the Chair of an ESMO meeting; stock ownership: Orion Pharma, Sartar Therapeutics.; Sally John: Employee of Biogen; Marc Jung: Employee of Boehringer Ingelheim; Katherine Klinger: Employee of Sanofi; Teijo Kuopio: Lecture fee from Amgen, Roche and MSD; Nathan Lawless: Employee of Boehringer Ingelheim; Simonne Longerich: Employee of Merck; Anders Malarstig: Employee of Pfizer Inc.; Joseph Maranville: Employee of Bristol Myers Squibb; Athena Matakidou: Employee of AstraZeneca; Sahar V. Mozaffari: Employee of Maze Therapeutics; Mari EK. Niemi: Employee of Novartis; Christopher J. O'Donnell: Employee of Novartis; Ma'en Obeidat: Employee of Novartis; George Okafo: Employee of Boehringer Ingelheim; Antti Palomaki: Consulting fee from Abbvie, Amgen and Pfizer, lecture free from Pfizer and Sanofi.; Jukka Partanen: Employee of the Finnish Red Cross Blood Service; Dirk S. Paul: Employee of AstraZeneca; Rion K. Pendergrass: Employee of Genentech; Slave Petrovski: Employee of AstraZeneca; Adam Platt: Employee of AstraZeneca; David Pulford: Employee of GlaxoSmithKline; Neha Raghavan: Employee of Merck; Fedik Rahimov: Employee of AbbVie Inc.; Deepak Rajpal: Employee of Sanofi; Nicole A. Renaud: Employee of Novartis; Bridget Riley-Gillis: Employee of AbbVie Inc.; Veikko Salomaa: Received a honorarium from Sanofi for consulting. Ongoing research collaboration with Bayer Ltd. (All unrelated to the present study).; Richard Siegel: Employee of Novartis; Jae Hoon Sul: Employee of Merck; Ioanna Tachmazidou: Employee of AstraZeneca; Pentti Tienari: Lecture or consulting fee from Alexion, Roche, Merck, Janssen-Cilag, Novartis, Biogen (unrelated to this work); Joni A. Turunen: Lecture fee from Blueprint Genetics Finland, and the advisory board of Novartis Finland (unrelated this work); Jacob C. Ulirsch: J.C.U. has received compensation for consulting from Goldfinch Bio and is an employee of Patch Biosciences.; Jeffrey Waring: Employee of AbbVie Inc.; Dawn Waterworth: Employee of Janssen Research & Development; Robert Yang: Employee of Janssen Biotech; Caroline Fox: Employee of Merck; Robert Plenge: Employee of Bristol Myers Squibb; Mark McCarthy: Employee of Genentech; Heiko Runz: Employee of Biogen; Mark J. Daly: Founder of Maze Therapeutics; Aarno Palotie: Member of the Pfizer Genetics Scientific Advisory PanelFunding StatementThe FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme Corp., Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (THL), approval number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3 the Social Insurance Institution (KELA) KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, and Statistics Finland TK-53-1041-17. The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 5 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall summary statistics described here are freely available.(www.finngen.fi/en/access_results).